FindTrial
Sign In

Autogene cevumeran

DRUG4 trials

Sponsors

Genentech, Inc., Hoffmann-La Roche

Conditions

Adenocarcinoma, Pancreatic DuctalAdvanced MelanomaBladder CancerColorectal CancerHead and Neck CancerMelanomaMuscle-invasive Urothelial CarcinomaNon-Small Cell Lung Cancer

Phase 1

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
CompletedNCT03289962
Genentech, Inc.Bladder Cancer, Colorectal Cancer, Head and Neck Cancer +5
Start: 2017-12-21End: 2025-07-01Updated: 2026-06-08

Phase 2

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.
CompletedNCT03815058
Genentech, Inc.Advanced Melanoma
Start: 2018-12-21End: 2025-01-21Updated: 2026-01-30
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
Active, not recruitingNCT05968326
Genentech, Inc.Adenocarcinoma, Pancreatic Ductal
Start: 2023-10-18End: 2031-01-01Target: 260Updated: 2026-09-09
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Active, not recruitingNCT06534983
Hoffmann-La RocheMuscle-invasive Urothelial Carcinoma
Start: 2024-12-09End: 2027-11-10Target: 62Updated: 2026-08-06

Related Papers

Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Nature Medicine2025-01-0165 citations
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
Nature Medicine2023-10-23210 citations
Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy
Cancer Science & Research2021-12-30